Jan Cools

This paper shows that DNMT3A-mutant blood stem cells, present but undetectable in young donors, can expand into clonal hematopoiesis decades after transplantation. The authors highlight that environmental pressures, not just new mutations, drive
this process.

Read here 👉https://bit.ly/3XLdF1m

#HemaSphere is heading to #ASH25 Are you interested to learn more? Looking to discuss your manuscript? Curious about who we are? Reach out - we can set a meeting time. Jessica will also be available at the #EHA booth (1482) at various times. See you in Orlando!

Explore the latest research lurking in our October issue… if you dare! 🎃👻🧟‍♀️http://bit.ly/4haMwh3

Looking forward to this exciting meeting and to represent @hemasphere-journal.bsky.social in this session!

Great mix of art & science at the Art Science Museum in Singapore.

In this study the authors show how cancer associated fibroblasts and their spatial architecture in the tumor microenvironment impact survival in patients with cHL. 

Read more about it here 👉https://bit.ly/4mdhPK6

Exciting to share the new impact factor of @hemasphere-journal.bsky.social, the #openaccess journal of the European Hematology Association (EHA).
The 2024 Journal Impact Factor is 14.6 - ranking as number 5 of 99 hematology journals (Source: Journal Citations Reports, Clarivate).

🚨Today! @ 15:45, MiCo room CORAL 6 
We warmly invite you to the HemaSphere Scientific Session where we will dive into 3 of our exciting + cutting-edge biology publications. Hope to see you there!
🕰️: 15:45 - 16:45
📍: Room CORAL 6, #EHA2025
🎤: https://bit.ly/4koLwXk

Thank you so much, Charley !

Thank you Marlies !!

Thank you EHA, for honoring me with the Education and Mentoring Award. Thank you Peter Marynen and Gary Gilliland for being such inspiring mentors to me! Thank you to all my trainees, all current and past members of my research group. #EHA2025 @hemasphere-journal.bsky.social

Heading to #EHA2025 in Milan in 1.5(ish) weeks? HemaSphere has 2 exciting sessions on the program!
📌Peer Review Workshop: Fri 13 June, 13:30 - 15:00
💡Learn + master the peer review role/process
📌HemaSphere Scientific Session: Sat 14 June, 15:45 - 16:45
💡Dive into 3 of our cutting-edge biology papers

Was a nice experience 😊

This study examines the frequency of recurring gene mutations and their interplay with well-known biomarkers in female and male patients, between 18-80 years, with ref/rel DLBCL compared to patients with CR to identify biological risk factors associated with treatment response👉https://bit.ly/4ihynhR

If you are interested in learning about #PDX models in in vivo drug testing, take the time to listen to the following @hemasphere-journal.bsky.social podcast featuring Prof Richard Lock. 👇

Single‐cell DNA and surface protein characterization of high hyperdiploid acute lymphoblastic leukemia at diagnosis and during treatment High hyperdiploid (HeH) B-cell acute lymphoblastic leukemia (B-ALL) is the most prevalent subtype of childhood ALL. This leukemia is characterized by trisomies and tetrasomies of specific chromosomes...

Happy to share our new insights in the variant mutations driving high hyperdiploid acute lymphoblastic #leukemia - always new discoveries when you go to the #single-cell level… @hemasphere-journal.bsky.social

onlinelibrary.wiley.com/doi/full/10....

Great podcast! There is a large variety on the quality of preclinical studies and the study discussed here is really top!! Published in @hemasphere-journal.bsky.social

This study quantified Bcl-2 family protein expression in newly diagnosed MM patients. High levels of Bad and Puma proteins were linked to longer OS. Bcl-2 protein ratios predicting venetoclax sensitivity distinguished patients with shorter progression times 👉https://bit.ly/4fUpV6c

We're proud to be fully open access - from day one, in fact.

On my way to Prague for their national hematology meeting, with my ‘retro’ EHA bag… this must be very old considering the logo…but still very useful 😊

📢 Authors evaluated the efficacy JPX-0700 and JPX-0750 as dual STAT3/5 inhibitors, reducing leukemic cell growth in AML/NKCL models. These compounds target STAT3/5 signaling, inducing cell death and growth arrest and exhibit synergistic effects w/ approved chemotherapeutics👉https://bit.ly/42oMtJp

Genetics is amazing 😊

2024 has been a successful year for HemaSphere Journal!
 800+ manuscript submissions
 increasing impact in the field
 insightful graphical abstracts
 another podcast season
 ...and of course, excellent research!

We extend a warm thank you to all authors, reviewers & readers ❤️

📖HemaSphere's December issue is now complete 👉https://bit.ly/HS_Dec2024 and as always, is 100% #OpenAccess. Please enjoy reading and feel free to share with your networks.

Microbes support normal blood production! Authors in this recently published article report on the microbes and microbial metabolites missing from pediatric patients with antibiotic-associated neutropenia. @TheKingLab 👉https://bit.ly/4fUXyWe

It was great to have you in the team!!

Save the date for ISEH 2025! View travel details and Annual Scientific Meeting Speakers here: www.iseh.org/page/iseh2025

This pop-based study examines COD in 20K+ CLL pts in the Netherlands from 1996-2020. This analysis shows a noticeable ⬇️ in CLL-attributed deaths & other causes yet as CLL is registered as the most prevalent COD this emphasizes the relevance of CLL-centric clinical strategies👉https://bit.ly/4iqC859